LifeStance Health Group (NASDAQ:LFST) Reaches New 1-Year High After Analyst Upgrade

Key Points

• LifeStance Health Group shares surged 11% to a new 52-week high of $12.06 after BTIG Research raised its price target from $15 to $16 and maintained a buy rating.
• Analyst sentiment remains favorable, with the stock carrying a consensus “Moderate Buy” rating and an average price target of $11.62, supported by recent target increases from Canaccord Genuity and KeyCorp.
• The company recently exceeded quarterly expectations, reporting adjusted earnings of $0.06 per share versus estimates of $0.03 and revenue of $435.35 million, up 26.1% year over year. However, insiders sold more than 7.6 million shares worth approximately $62.9 million over the past three months.

LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) shares reached a new 52-week high during trading on Monday after BTIG Research raised their price target on the stock from $15.00 to $16.00. BTIG Research currently has a buy rating on the stock. LifeStance Health Group traded as high as $12.06 and last traded at $12.0580, with a volume of 1944465 shares changing hands. The stock had previously closed at $10.84.

Other analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of LifeStance Health Group from a "strong-buy" rating to a "buy" rating in a report on Saturday, July 25th. Canaccord Genuity Group lifted their target price on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company a "buy" rating in a research note on Tuesday, July 21st. KeyCorp boosted their price target on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company an "overweight" rating in a research report on Monday, July 13th. Weiss Ratings reiterated a "hold (c-)" rating on shares of LifeStance Health Group in a report on Wednesday, May 27th. Finally, The Goldman Sachs Group started coverage on shares of LifeStance Health Group in a research report on Friday, June 5th. They set a "neutral" rating and a $9.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, LifeStance Health Group presently has an average rating of "Moderate Buy" and a consensus target price of $11.62.

Insider Transactions at LifeStance Health Group

In other news, Director Robert Bessler sold 894,337 shares of the firm's stock in a transaction on Friday, June 26th. The stock was sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the completion of the transaction, the director directly owned 539,763 shares in the company, valued at $5,467,799.19. This trade represents a 62.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Eric Shuey sold 243,362 shares of the company's stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $1,951,763.24. Following the completion of the transaction, the director owned 867,562 shares in the company, valued at approximately $6,957,847.24. The trade was a 21.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 7,612,394 shares of company stock valued at $62,938,451. Insiders own 3.50% of the company's stock.

Hedge Funds Weigh In On LifeStance Health Group

A number of hedge funds have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL purchased a new stake in LifeStance Health Group in the third quarter worth approximately $1,040,000. Silversmith Partners I GP LLC purchased a new stake in LifeStance Health Group during the 4th quarter valued at $100,842,000. First Eagle Investment Management LLC raised its stake in LifeStance Health Group by 13.3% during the 4th quarter. First Eagle Investment Management LLC now owns 1,496,466 shares of the company's stock valued at $10,535,000 after buying an additional 176,000 shares during the last quarter. Moran Wealth Management LLC purchased a new stake in LifeStance Health Group during the 1st quarter valued at $953,000. Finally, Jennison Associates LLC lifted its holdings in shares of LifeStance Health Group by 38.5% during the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company's stock valued at $65,157,000 after buying an additional 2,843,388 shares during the period. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

LifeStance Health Group Trading Up 11.0%

The stock has a market capitalization of $4.66 billion, a PE ratio of 92.66 and a beta of 1.14. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.18. The stock has a 50 day moving average price of $9.95 and a 200-day moving average price of $8.06.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.03 by $0.03. The company had revenue of $435.35 million for the quarter, compared to the consensus estimate of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.LifeStance Health Group's revenue was up 26.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.01) earnings per share. Sell-side analysts expect that LifeStance Health Group, Inc. will post 0.12 earnings per share for the current year.

About LifeStance Health Group

LifeStance Health Group NASDAQ: LFST is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source